Stay updated on Effect of Oral AT1001 in Fabry Disease Clinical Trial
Sign up to get notified when there's something new on the Effect of Oral AT1001 in Fabry Disease Clinical Trial page.

Latest updates to the Effect of Oral AT1001 in Fabry Disease Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.8%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check26 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check40 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check54 days agoChange DetectedThe page has removed a citation regarding the assessment of plasma lyso-Gb3 for clinical monitoring in Fabry disease, which included an erratum reference.SummaryDifference0.3%
Stay in the know with updates to Effect of Oral AT1001 in Fabry Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Oral AT1001 in Fabry Disease Clinical Trial page.